Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Wednesday. The firm issued a sell rating on the stock.

Oragenics Stock Down 5.6 %

Shares of Oragenics stock opened at $1.53 on Wednesday. Oragenics has a 52-week low of $1.00 and a 52-week high of $7.74. The business has a 50 day moving average price of $1.61. The stock has a market capitalization of $6.85 million, a P/E ratio of -0.18 and a beta of 0.58.

Oragenics (NYSE:OGEN) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new stake in Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent reporting period. 18.71% of the stock is owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.